Tous Actualités
Suivre
Abonner AmVac AG

AmVac AG

Ariane Meynert Joins Swiss AmVac AG

Zug (ots)

As of September 1, 2007 Ariane Meynert is
joining Swiss biotech company AmVac AG, Zug, as Managing Director in
charge of investor and public relations.
Management graduate Meynert comes from TOMORROW FOCUS AG in
Munich, a Hubert Burda Medien AG Group company where she was in
charge of developing investor and public relations for several years.
She previously supervised, in the same function, the successful IPO
of Süss Microtec AG.
Melinda Karpati, CEO of AmVac AG, said, "I am delighted to have
been able to recruit Ariane Meynert for this key position preceding
AmVac AG's forthcoming IPO in the Zurich stock market's SWX segment.
With her experience and her personality, she will make a successful
contribution toward AmVac AG's planned stock market listing."
About AmVac AG
AmVac AG is a young biopharmaceutical company based in Switzerland
that is concentrating in the high-yield pharmaceutical industry on an
especially high-growth market segment. An average annual growth rate
of 13% is forecast until 2010 for the vaccines market, compared with
6% for pharmaceuticals in general. AmVac products are further
characterized by meeting unfulfilled therapy requirements in the
fields of urology and gynecology. AmVac has to date licensed and
further developed two advanced immunotherapeutic drugs with gold
standard potential. Further products are in the planning stage.

Contact:

AmVac AG
Ariane Meynert
Metallstrasse 4
CH-6300 Zug
Switzerland
Phone: +41/41/725'32'32
Fax: +41/41/725'32'33
Cell: +41/79/793'34'19
+49/172-775-9212
Email: meynert@amvac.ch